Cargando…

A rare case report of apixaban-induced lichenoid eruption

With recent increase in the use of direct oral anticoagulants (DOACs), several new cases of adverse drug reactions (ADRs) have been identified in pharmacovigilance surveys. These ADRs can result in significant mortality and morbidity if not identified and treated promptly. It is important for physic...

Descripción completa

Detalles Bibliográficos
Autores principales: Patil, Tanvi, Hanna, Suzanne, Torre, Wayne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436782/
https://www.ncbi.nlm.nih.gov/pubmed/32874531
http://dx.doi.org/10.1177/2042098620937884
_version_ 1783572545066237952
author Patil, Tanvi
Hanna, Suzanne
Torre, Wayne
author_facet Patil, Tanvi
Hanna, Suzanne
Torre, Wayne
author_sort Patil, Tanvi
collection PubMed
description With recent increase in the use of direct oral anticoagulants (DOACs), several new cases of adverse drug reactions (ADRs) have been identified in pharmacovigilance surveys. These ADRs can result in significant mortality and morbidity if not identified and treated promptly. It is important for physicians to recognize that immunologically mediated delayed hypersensitivity reactions, although rare in occurrence, can have significant impact on patient’s quality of life. To the best of our knowledge, we report the first case of lichenoid eruption associated with apixaban. We further provide evidence of tolerance to rivaroxaban in the same patient. PLAIN LANGUAGE SUMMARY: Apixaban-induced lichenoid eruption Well documented case reports, although providing evidence of probable causal relationship between a drug and specific adverse drug reactions (ADRs), can increase awareness amongst clinicians treating patients with direct oral anticoagulants (DOACs), especially with its rapid utilization. Rare ADRs are difficult to detect as clinical trials of DOACs lacked enough patient sample, making post-marketing reporting of such events important so both patients and clinicians can be vigilant to help with prompt recognition of such symptoms. We report the first case of lichenoid eruption hypersensitivity reaction associated with apixaban in patient with tolerance to rivaroxaban.
format Online
Article
Text
id pubmed-7436782
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-74367822020-08-31 A rare case report of apixaban-induced lichenoid eruption Patil, Tanvi Hanna, Suzanne Torre, Wayne Ther Adv Drug Saf Case Report With recent increase in the use of direct oral anticoagulants (DOACs), several new cases of adverse drug reactions (ADRs) have been identified in pharmacovigilance surveys. These ADRs can result in significant mortality and morbidity if not identified and treated promptly. It is important for physicians to recognize that immunologically mediated delayed hypersensitivity reactions, although rare in occurrence, can have significant impact on patient’s quality of life. To the best of our knowledge, we report the first case of lichenoid eruption associated with apixaban. We further provide evidence of tolerance to rivaroxaban in the same patient. PLAIN LANGUAGE SUMMARY: Apixaban-induced lichenoid eruption Well documented case reports, although providing evidence of probable causal relationship between a drug and specific adverse drug reactions (ADRs), can increase awareness amongst clinicians treating patients with direct oral anticoagulants (DOACs), especially with its rapid utilization. Rare ADRs are difficult to detect as clinical trials of DOACs lacked enough patient sample, making post-marketing reporting of such events important so both patients and clinicians can be vigilant to help with prompt recognition of such symptoms. We report the first case of lichenoid eruption hypersensitivity reaction associated with apixaban in patient with tolerance to rivaroxaban. SAGE Publications 2020-08-17 /pmc/articles/PMC7436782/ /pubmed/32874531 http://dx.doi.org/10.1177/2042098620937884 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Patil, Tanvi
Hanna, Suzanne
Torre, Wayne
A rare case report of apixaban-induced lichenoid eruption
title A rare case report of apixaban-induced lichenoid eruption
title_full A rare case report of apixaban-induced lichenoid eruption
title_fullStr A rare case report of apixaban-induced lichenoid eruption
title_full_unstemmed A rare case report of apixaban-induced lichenoid eruption
title_short A rare case report of apixaban-induced lichenoid eruption
title_sort rare case report of apixaban-induced lichenoid eruption
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436782/
https://www.ncbi.nlm.nih.gov/pubmed/32874531
http://dx.doi.org/10.1177/2042098620937884
work_keys_str_mv AT patiltanvi ararecasereportofapixabaninducedlichenoideruption
AT hannasuzanne ararecasereportofapixabaninducedlichenoideruption
AT torrewayne ararecasereportofapixabaninducedlichenoideruption
AT patiltanvi rarecasereportofapixabaninducedlichenoideruption
AT hannasuzanne rarecasereportofapixabaninducedlichenoideruption
AT torrewayne rarecasereportofapixabaninducedlichenoideruption